Heterocyclic Estrogen Receptor Modulators for Metastatic Breast Cancer

Solution Overview

Problem

There is a need for new estrogen receptor-alpha (ER-a) targeting agents that are effective in treating metastatic disease and overcoming acquired resistance, particularly in hormone receptor-positive metastatic breast cancer post-anti-estrogen therapy, as existing therapies often fail to provide lasting tumor regression and are prone to resistance.

Innovation Solution

Development of compounds that act as estrogen receptor degraders or modulators, specifically designed to diminish estrogen receptor activity, including estrogen receptor antagonist and degrader compounds that can be administered as pharmaceutical compositions to treat various ER-related diseases and conditions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing anti-estrogen therapies are used to treat hormone receptor-positive metastatic breast cancer, then initial tumor regression may be achieved, but treatment resistance develops and tumor regression is not lasting

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent changes the mechanism of action parameter from simple receptor antagonism to receptor degradation. The compounds induce ubiquitination and proteasomal degradation of estrogen receptors, fundamentally altering how the therapy interacts with the target to achieve more durable tumor regression and overcome resistance

Inventive Principle:
Principle #35Parameter changes

2Reliability

If existing estrogen receptor antagonists are used, then estrogen receptor activity is blocked, but acquired resistance develops reducing therapeutic effectiveness

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the estrogen receptor from the system through degradation rather than just blocking its activity. The compounds promote ubiquitination and proteasomal degradation, physically removing the receptor from cells to eliminate the target for resistance development

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

Instead of blocking receptor activity (antagonism), the patent inverts the approach by promoting receptor degradation. This fundamental inversion of the mechanism of action transforms temporary blockade into permanent removal, overcoming resistance

Inventive Principle:
Principle #13The other way round (Inversion)

3Reliability

If conventional estrogen receptor targeting agents are used, then some therapeutic effect is achieved, but tumor invasiveness is not sufficiently reduced

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the therapeutic parameter from receptor activity modulation to receptor quantity reduction. By inducing proteasomal degradation, the compounds achieve both therapeutic effect and reduced tumor invasiveness through sustained lower receptor levels

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP3303326B1Heterocyclic estrogen receptor modulators and uses thereof
Publication Date: 2020.12.16
  • EP3303326B1 patent drawing
  • EP3303326B1 patent drawing
  • EP3303326B1 patent drawing

AI summary

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.